Core Viewpoint - Integra LifeSciences Holdings Corporation reported an earnings miss for Q1 2025, with adjusted EPS of 41 cents, falling short of estimates and showing a significant year-over-year decline of 25.5% [1][2][11] Financial Performance - Total revenues for Q1 2025 increased by 3.7% year over year to $382.7 million, slightly exceeding consensus estimates by 0.1% [3] - Organic revenue declined by 3.5% year over year, indicating challenges in core operations [3][11] - Gross profit decreased by 6% year over year to $194.4 million, with gross margin contracting by 526 basis points to 50.8% due to a 16.2% rise in the cost of goods sold [6] - Selling, general and administrative expenses rose by 9.5% to $181.5 million, while research and development expenses fell by 8.3% to $24.7 million [6] Segment Performance - Revenues in the Codman Specialty Surgical segment rose by 9.4% year over year to $280.7 million, although organic growth was down by 1.1% [4] - Neurosurgery sales within this segment fell by 4.7% organically, attributed to shipping holds [4] - Tissue Technologies revenues totaled $102 million, down 9.3% year over year, with notable declines in Private Label sales due to supply delays [5] Financial Position - At the end of Q1 2025, the company had approximately $239.1 million in cash and cash equivalents, down from $246.4 million at the end of Q4 2024 [8] - Cumulative net cash outflow from operating activities was $11.26 million, contrasting with cash inflows of $15.76 million a year ago [8] Guidance - For 2025, the company reaffirmed its revenue guidance of $1.650-$1.715 billion, indicating growth of 2.4%-6.5% [9] - Adjusted EPS forecast was reduced to a range of $2.19-$2.29 from a previous range of $2.41-$2.51 [9] - For Q2 2025, expected revenues are projected between $390-$400 million, reflecting a decline of 6.8%-4.4% [10] Strategic Insights - Despite the earnings miss, the company reported positive contributions from the Acclarent acquisition and double-digit growth in several product lines [12] - The company is focusing on advancing its Compliance Master Plan, expanding its international portfolio, and enhancing leadership [12]

三叶草生物被讨要退款超两亿美元，6400万剂疫苗 不买了 三叶草生物与全球疫苗免疫联盟之间的新冠疫苗预购协议突遭变故。 3月24日晚间，三叶草生物称，公司全资附属子公司三叶草香港收到全球疫苗免疫联盟（简称： GAVI）发出的两份函件。3月21日，GAVI声称其单方面终止与三叶草香港的预购协议，并且要求三叶 草香港退还预付款项2.24亿美元。 三叶草生物称其拒绝有关退款的要求，认为基于预购协议条款该等要求缺乏依据，并将全力以赴、 严正有力地维护自身权益。据其所知，截至本公告日期，并无任何有关上述索偿要求的法律程序展开。 前述公告并未说明GAVI基于何种条款和要求终止合约及索要预付款。3月25日，界面新闻记者向全 球疫苗免疫联盟发送邮件询问此事，截至发稿，尚未收到答复。除上述公告内容外，三叶草生物回复界 面新闻称，公司曾在2022年9月发布自愿公告，公告中明确说明，公司已于2022年9月收到Gavi支付的 2.24亿（224百万）美元，作为购买最初6400万剂订单所需的不可退回材料的预付款。 3月25日开盘，三叶草生物股价下跌，午间股价跌超7%。截至收盘，三叶草生物报0.3港元/股，跌 7.69%，当前市值为3. ...